Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

European Heart Journal

Volumn 36, Issue 28, 2015, Pages 1805-1811

  Cappato, Riccardo ^a,b   Marchlinski, Francis E ^c   Hohnloser, Stefan H ^d   Naccarelli, Gerald V ^e   Xiang, Jim ^f   Wilber, David J ^g   Ma, Chang Sheng ^h   Hess, Susanne ⁱ   Wells, Darryl S ^j   Juang, George ^k   Vijgen, Johan ^l   Hügl, Burkhard J ^m   Balasubramaniam, Richard ⁿ   De Chillou, Christian ^o   Davies, D Wyn ^p   Fields, L Eugene ^f   Natale, Andrea ^q  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Humanitas Gavazzeni Hospital   (Italy)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^g LOYOLA UNIVERSITY CHICAGO   (United States)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ BAYER PHARMA AG   (Germany)

^j Swedish Heart and Vascular Institute   (United States)

^k Heart and Arrhythmia Care of New York   (United States)

^l JESSA HOSPITAL   (Belgium)

^m Marienhaus Klinikum St Elisabeth Klinik   (Germany)

ⁿ ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^o UNIVERSITY HOSPITAL OF NANCY   (France)

^p IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^q TEXAS CARDIAC ARRHYTHMIA INSTITUTE   (United States)

more..

Author keywords

Atrial fibrillation; Catheter ablation; Oral anticoagulant; Thromboembolism; Uninterrupted

Indexed keywords

ANTIVITAMIN K; HEPARIN; RIVAROXABAN; ANTIARRHYTHMIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; VITAMIN K GROUP;

ADULT; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING TIME; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GINGIVA BLEEDING; HEART INFARCTION; HEMATURIA; HUMAN; INTRAOCULAR HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NONVALVULAR ATRIAL FIBRILLATION; ORAL BLEEDING; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD LOSS, SURGICAL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; OPERATION DURATION; PROCEDURES; PROSPECTIVE STUDY; PULMONARY VEIN; RECURRENT DISEASE; REOPERATION; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BLOOD LOSS, SURGICAL; CATHETER ABLATION; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; OPERATIVE TIME; PROSPECTIVE STUDIES; PULMONARY VEINS; RECURRENCE; REOPERATION; RIVAROXABAN; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VITAMIN K;

EID: 84938411952     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv177     Document Type: Article

References (30)

1. Haïssaguerre M, Jaïs P, Shah DC, Gencel L, Pradeau V, Garrigues S, Chouairi S, Hocini M, Le Métayer P, Roudaut R, Clémenty J. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996;7:1132-1144.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
3. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, Fassini G, Tondo C, Schweikert RA, Natale A. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129:2638-2644.
4. Gopinath D, Lewis WR, Di Biase L, Natale A. Pulmonary vein antrum isolation for atrial fibrillation on therapeutic coumadin: special considerations. J Cardiovasc Electrophysiol 2011;22:236-239.
5. Page SP, Siddiqui MS, Finlay M, Hunter RJ, Abrams DJ, Dhinoja M, Earley MJ, Sporton SC, Schilling RJ. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance? J Cardiovasc Electrophysiol 2011;22:265-270.
6. Hakalahti A, Uusimaa P, Ylitalo K, Raatikainen MJ. Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment. Europace 2011;13:640-645.
7. Gautam S, John RM, Stevenson WG, Jain R, Epstein LM, Tedrow U, Koplan BA, McClennen S, Michaud GF. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2011;22:248-254.
8. Chen J, Todd DM, Hocini M, Larsen TB, Bongiorni MG, Blomström-Lundqvist C; Scientific Initiative Committee, European Heart Rhythm Association. Current periprocedural management of ablation for atrial fibrillation in Europe: results of the European Heart Rhythm Association survey. Europace 2014;16:378-381.
9. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm (accessed 6 April 2015).
10. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022406s009lbl.pdf (accessed 6 April 2015).
11. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, Swarup V, Chalhoub F, Atkins D, Bommana S, Verma A, Sanchez JE, Burkhardt JD, Barrett CD, Baheiry S, Ruskin J, Reddy V, Natale A. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982-988.
12. Bin Abdulhak AA, Khan AR, Wimmer AP. Dabigatran in catheter ablation of atrial fibrillation: a call for a randomized control trial. Amer J Cardiol 2014;113:2087-2088.
13. Weitz JI, Healey JS, Skanes AC, Verma A. Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. Circulation 2014;129:1688-1694.
14. Naccarelli GV, Gonzalez MD. Catheter ablation of atrial fibrillation: the need for studiesto assess the efficacy and safety of novel anticoagulants. J Interv Cardiol Electrophysiol 2013;36:3-4.
15. Naccarelli GV, Cappato R, Hohnloser SH, Marchlinski FE, Wilber DJ, Xiang J, Ma C, Hess S, Davies DW, Fields LE, Natale A; VENTURE-AF Investigators. Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation. J Interv Card Electrophysiol 2014;41:107-116.
16. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-2747.
17. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-694.
18. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107:379-387.
19. Pothineni NV, Deshmukh A, Pant S, Patel NJ, Badheka A, Chothani A, Shah N, Mehta K, Savani GT, Singh V, Grover P, Bhalara V, Patel N, Arora S, Rathod A, Viles-Gonzalez J, Paydak H. Complication rates of atrial fibrillation ablations: comparison of safety outcomes from real world to contemporary randomized control trials. Int J Cardiol 2014;175:372-373.
20. Gupta A, Perera T, Ganesan A, Sullivan T, Lau DH, Roberts-Thomson KC, Brooks AG, Sanders P. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm Electrophysiol 2013;6:1082-1088.
21. Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, Grover P, Singh V, Vallurupalli S, Savani GT, Badheka A, Tuliani T, Dabhadkar K, Dibu G, Reddy YM, Sewani A, Kowalski M, Mitrani R, Paydak H, Viles-Gonzalez JF. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation 2013;128:2104-2112.
22. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, McMurtry MS, Connolly S, Cox JL, Dorian P, Ivers N, Leblanc K, Nattel S, Healey JS; CCS Atrial Fibrillation Guidelines Committee. 2014 Focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 2014;30:1114-1130.
23. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of neworal anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651.
24. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheterand Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528-606.
25. Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR, Pathak R, Jalota L, Bhandari Y, Donato A. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2014;114:577-582.
26. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace 2014;16:1443-1449.
27. Dillier R, Ammar S, Hessling G, Kaess B, Pavaci H, Buiatti A, Semmler V, Kathan S, Hofmann M, Lennerz C, Kolb C, Reents T, Deisenhofer I. Safety of Continuous Periprocedural Rivaroxaban for Patients Undergoing Left Atrial Catheter Ablation Procedures. Circ Arrhythm Electrophysiol 2014;7:576-582.
28. Providência R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, Hireche H, Morais J, Boveda S. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace 2014;16:1137-1144.
29. Arshad A, Johnson CK, Mittal S, Buch E, Hamam I, Tran T, Shaw RE, Musat D, Preminger M, Sichrovsky T, Herweg B, Shivkumar K, Hummel J, Steinberg JS. Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study. Pacing Clin Electrophysiol 2014;37:665-673.
30. Armbruster HL, Lindsley JP, Moranville MP, Habibi M, Khurram IM, Spragg DD, Berger RD, Calkins H, Marine JE. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Ann Pharmacother 2015;49:278-284.